AbCellera (ABCL) announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application for ABCL575, an investigational antibody antagonist targeting OX40 ligand that is being developed for the treatment of moderate-to-severe atopic dermatitis, with potential applications to other inflammatory and autoimmune conditions. The Phase 1 study is anticipated to begin in Q3 of 2025 and will evaluate the safety and pharmacokinetics of ABCL575 administered subcutaneously in healthy participants.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABCL:
- AbCellera price target lowered to $10 from $28 at Truist
- AbCellera Biologics Receives Health Canada Approval for Trial
- AbCellera receives NOL from Health Canada for ABCL635 clinical trial application
- AbCellera Wins Patent Appeal Against Bruker
- AbCellera says Federal Circuit rejects Bruker Cellular’s invalidity challenge